Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme

Current Stem Cell Research and Therapy

Volumn 5, Issue 3, 2010, Pages 273-276

  Gutova, Margarita ^a   Najbauer, Joseph ^a   Chen, Mike Y ^a   Potter, Philip M ^b   Kim, Seung U ^c,d   Aboody, Karen S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Chung Ang University College of Medicine   (South Korea)

Author keywords

CPT 11; Enzyme prodrug therapy; Irinotecan; Melanoma; Neural stem cells; SN 38; Stem cell mediated drug delivery

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; INTERLEUKIN 6; INTERLEUKIN 8; IRINOTECAN; MONOCYTE CHEMOTACTIC PROTEIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CYTOKINE; DRUG DERIVATIVE; ENZYME INHIBITOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL IMMORTALIZATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; NEURAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; CELL MOTION; CYTOLOGY; ENZYMOLOGY; GENETICS; MELANOMA; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; RABBIT; STEM CELL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARBOXYLESTERASE; CELL LINE, TUMOR; CELL MOVEMENT; CYTOKINES; ENZYME INHIBITORS; HUMANS; MELANOMA; NEURONS; RABBITS; STEM CELLS;

EID: 77957660560     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488810791824421     Document Type: Article

References (18)

1. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355(1): 51-65.
2. Larson AR, Konat E, Alani RM. Melanoma biomarkers: current status and vision for the future. Nat Clin Pract Oncol 2009; 6(2): 105-117.
3. Gray-Schopfer VC. Wellbrock, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445(7130): 851-857.
4. Russo AE, Torrisi E, Bevelacqua Y, et al. Melanoma: molecular pathogenesis and emerging target therapies (Review). Int J Oncol 2009; 34(6): 1481-1489.
5. Aboody KS, Brown A, Rainov NG, et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97(23): 12846-12851.
6. Benedetti S, Pirola B, Pollo B, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000; 6(4): 447-450.
7. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cellmediated tumor selective gene therapy. Gene Ther 2008; 15(10): 739-752.
8. Aboody KS, Najbauer J, Schmidt NO, et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol 2006; 8(2): 119-126.
9. Kim SK, Kim SU, Park IH, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006; 12(18): 5550-5556.
10. Kim SU, Nagai A, Nakagawa E, et al. Production and characterization of immortal human neural stem cell line with multipotent differentiation property. Methods Mol Biol 2008; 438: 103-121.
11. Najbauer J, Danks MK, Schmidt N, Kim SU, Aboody KS. Neural stem cell-mediated therapy of primary and metastatic solid tumors. In: Bertolotti R, Ozawa K, Eds. Autologous and cancer stem cell gene therapy. World Scientific: Singapore 2007; pp. 335-372.
12. Kim SU. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 2004; 24(3): 159-171.
13. Gutova M, Najbauer J, Frank RT, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008; 26(6): 1406-1413.
14. Gutova M, Najbauer J, Gevorgyan A, et al. Identification of uPARpositive chemoresistant cells in small cell lung cancer. PLoS One 2007; 2(2): e243.
15. Potter PM, Pawlik CA, Morton CL, Naeve CW, Danks MK. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998; 58(12): 2646- 2651.
16. Dumez H, Awada A, Piccart M, et al. A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 2006; 17(7): 1158-1165.
17. Aboody KS, Bush RA, Garcia E, et al. Development of a tumorselective approach to treat metastatic cancer. PLoS One 2006; 1: e23.
18. Danks MK, Yoon KJ, Bush RA, et al. Tumor-targeted enzyme/ prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007; 67(1): 22-25.